Novartis Venture Fund

Overview

Novartis's life-sciences-focused corporate venture arm, investing mainly at Seed/Series A in biopharma since 1996. Continues to invest actively under this name (no rebrand or spin-out found; confirmed active 2026 investments). Reported to manage roughly USD 750 million, per third-party aggregator data rather than an official Novartis figure -- its precise legal relationship to Novartis (fully owned vs. externally managed) was not independently confirmed. Distinct from the generic 'Novartis' corporate profile already on file, which covers the parent pharmaceutical company rather than this dedicated venture vehicle.

Key Facts

Type

Corporate Venture Capital

Geography focus

North America and Europe